Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In the R6/2 mouse model of Huntington's disease (HD) we examined the effects of a number of behavioral and pharmacological manipulations aimed at rescuing the progressive loss of synaptic communication between cerebral cortex and striatum. Two cohorts of transgenic mice with ~110 and 210 CAG repeats were utilized. Exercise prevented the reduction in striatal medium-sized spiny neuron membrane capacitance but did not reestablish synaptic communication. Activation of adenosine A2A type receptors renormalized postsynaptic activity to some extent. Finally, the ampakine Cx614, which has been shown to prevent α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptor desensitization, slow deactivation, and facilitate glutamate release, induced significant increases in synaptic activity, albeit the effect was somewhat reduced in fully symptomatic, compared to control mice. With some limitations, each of these strategies can be used to delay and partially rescue phenotypic progression of HD in this model.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945295 | PMC |
| http://dx.doi.org/10.1371/currents.RRN1182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Astrocyte-neuron combined targeting for CYP46A1 gene therapy in Huntington's disease.
Acta Neuropathol Commun
August 2025
NeuroGenCell, Inserm U 1127, CNRS UMR 7225, ICM, Institut du Cerveau, Sorbonne Université, Paris, France.
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by an abnormal expansion of cytosine-adenine-guanosine (CAG) trinucleotidein the huntingtin gene. Mutant huntingtin (mHTT) expression in neurons and glial cells affects neuron and astrocyte functions and leads to the loss of medium spiny neurons of the striatum. Brain cholesterol pathway is severely affected by HTT mutation in neurons and astrocytes, contributing to HD pathogenesis.
View Article and Find Full Text PDFFatty Acid Profile in the Liver of Mice with Early- and Late-Onset Forms of Huntington's Disease.
Int J Mol Sci
July 2025
Department of Biochemistry and Clinical Physiology, Medical University of Gdansk, 80-210 Gdansk, Poland.
Huntington's disease (HD) is characterized by progressive neurodegeneration, but increasing evidence points to multisystemic involvement, including early hepatic steatosis in pediatric HD. Therefore, it is important to consider systemic alterations, particularly in liver lipid metabolism. In this study, we analyzed fatty acid (FA) profiles in two symptomatic HD mouse models: 2-month-old mice representing early-onset HD and 22-month-old () mice representing late-onset HD, along with age-matched wild-type () controls.
View Article and Find Full Text PDFNeuroprotective and gut health benefits of Ugni molinae in preclinical Huntington's disease models.
Exp Neurol
November 2025
Center for Integrative Biology, Universidad Mayor, Santiago, Chile; Center for Geroscience, Brain Health and Metabolism, Santiago, Chile; Escuela de Biotecnología, Universidad Mayor, Santiago, Chile. Electronic address:
Huntington's disease (HD) is an autosomal-dominant inherited neurological disorder caused by an unstable trinucleotide CAG repeat expansion at the N-terminus of the IT-15 gene, which encodes the ∼350 kDa huntingtin protein (Htt). This mutation confers toxic properties, promoting neuronal dysfunction and death through multiple mechanisms. Effective treatments for HD are still lacking.
View Article and Find Full Text PDFInsulin-like growth factor 2 reduces Huntington's disease aggregates via AKT and NF-κB signaling in huntington's disease.
Cell Biosci
July 2025
Department of Physiology, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.
Background: Aggregation of misfolded mutant Huntingtin (mHTT) is a pathological characteristic in Huntington’s disease (HD), implying clearance of mHTT is a therapeutical direction for this neurodegenerative disorder. Based on previous studies, Insulin-like growth factor 2 (IGF2) enhances microfilament polymerization in HD models; however, the role of IGF2 against mHTT aggregates is still unclear.
Results: Here, we demonstrate that IGF2 expression is significantly lower in symptomatic HD patients compared to presymptomatic individuals, and IGF2 activation mechanistically enhances phosphorylation of Protein Kinase B(AKT; serine/threonine kinase), which subsequently reduces mHTT aggregates in vitro.
The Role of Animal Models in Huntington's Disease Clinical Trials: Decoding Genetic, Non-Genetic, and Molecular Pathways.
Rev Recent Clin Trials
July 2025
Department of Pharmacology, Jayawantrao Sawant College of Pharmacy and Research, Savitribai Phule Pune University, Pune, 411028, India.
Background: Huntington's disease (HD) is a neurodegenerative disorder due to a CAG trinucleotide repeat expansion in the HD gene. Animal models have been instrumental in revealing the genetic and molecular bases of HD. While animal models cannot exactly model the human disease because of anatomical and lifespan differences, they are essential in revealing HD pathology and possible treatments.
View Article and Find Full Text PDF